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Abstract
CA 15-3 is a tumor marker that is used clinically to monitor breast cancer therapy and 
disease progression.  In this study, seven automated immunoassays for CA15-3 (Access 2, 
ADVIA Centaur, ARCHITECT i2000, AxSYM, Elecsys 2010, IMMULITE 2000, VITROS 
ECi) were evaluated for the following parameters: limit of detection, linearity, imprecision, 
method comparison and reference intervals. The limit of detection was < 1.0 kU/L for each 
method.  The analytic measurement ranges of the assays varied widely (see Table 1). 
Linearity studies demonstrated that the maximum average deviation from the target recovery 
ranged from 6.1% for the Access 2 to 12.3% for the ARCHITECT i2000. Total imprecision 
at a concentration of 14 kU/L ranged from a CV of 2.5% for the Elecsys 2010 to 6.0% for the 
IMMULITE 2000; at a concentration of 35 kU/L it ranged from 2.2% for the ARCHITECT 
i2000 to 4.2% for the Access 2; and at a concentration of 152 kU/L it ranged from 2.5% for 
the VITROS ECi to 5.2% for the IMMULITE 2000 (see Table 2). Method comparison 
studies were conducted using 100 samples and variable agreement with the ADVIA Centaur 
comparison method was found. Slopes ranged from 0.50 to 1.48 and correlation coefficients 
from 0.90 to 0.96 (see Figure 1). The ARCHITECT i2000 and the AxSYM methods with 
slopes of 1.07 and 1.06 respectively, and correlation coefficients of 0.96 demonstrated the 
highest agreement with the ADVIA Centaur comparison method. The upper 97.5% reference 
limits were determined using 120 samples (see Table 3). The upper 97.5% reference limits 
found for the Elecsys 2010, IMMULITE 2000 and VITROS ECi were above the 
manufacturer’s reference limits. Overall, all methods performed well. However, both method 
comparison and reference interval studies suggest differences that may be due to calibration, 
assay design, and/or the antibodies used. 
Introduction
CA 15-3 is a tumor marker that is recommended for  monitoring breast cancer therapy 
and disease progression, particularly management of metastasis. It is not recommended, 
however, for breast cancer screening. The CA 15-3 antigen is a mucin glycoprotein encoded 
by MUC1. MUC1 proteins or mucins are normally expressed on the apical side of  glandular 
epithelia of various organs  and serve to protect and lubricate surrounding cells. In breast 
cancer, particularly epithelial breast carcinoma, mucins become overexpressed and released 
into circulation. Elevated serum CA 15-3 levels can be detected by a number of commercially 
available automated immunoassays : Beckman-Coulter Access 2 (Beckman Coulter, Brea, 
CA), Abbott AxSYM (Abbott Diagnostics, Abbott Park, IL), Bayer ADVIA Centaur (Bayer 
Diagnostics, Tarrytown, NY), Abbott ARCHITECT i2000 ( Abbott Diagnostics, Abbott Park, 
IL), Roche Elecsys 2010 (Roche Diagnostics, Indianapolis, IN), DPC IMMULITE 2000 
(Diagnostics Products Corporation, Los Angeles, CA) and Ortho-Clinical Diagnostics 
VITROS ECi (Ortho-Clinical Diagnostics, Raritan, NJ) methods. The aim of  these studies 
was to evaluate these seven automated methods for  the following parameters: limit of 
detection, linearity, imprecision,  reference intervals and method comparison with the 
ADVIA Centaur as the comparison method.
Methods 
The limit of detection  was determined by performing two separate runs and  
averaging the mean. In each run, there were 10 replicates of the “0” material and  two  
replicates of the “non-zero” calibrator specific for each instrument and calculating 2 SD for 
the “0” material.  
One hundred samples submitted to our clinical laboratory and previously tested for 
CA 15-3 or CA 27.29 were used to assess linearity. Three such individual samples were run 
in triplicate on each analyzer. When appropriate, individual patient samples were first diluted 
with the manufacturer’s recommended diluent until they were within the previously reported 
analytical measurement range specific for each instrument.
Imprecision was estimated for all seven methods by using the standard commercially 
available Biorad Lyphocheck Tumor Marker Control (Low, or level 1), BioRad Lyphocheck
Tumor Marker Control (High or level 2)  and a high manufacturer quality control material 
specific for each instrument (exception: Access 2, not available). Samples were run in 
duplicate, on two separate runs per day, for five days, for a total of  20 replicates for each 
control level. The imprecision levels were analysed using the EP Evaluator Release 5 
software (David G. Rhoads Associates, Kenett Square, PA).
One hundred patient samples that were previously tested for CA15-3 or CA 27.29  on 
the ADVIA Centaur and represented female subjects between 32-90 yrs. of age (exception, 
one 61yr. old male) were used in the method comparison studies. Passing-Bablock regression 
analysis were calculated using the Analyse-it+ Clinical Laboratory version 1.63 software.
For the reference interval studies samples were obtained from 120 healthy female 
subjects that were not taking any prescription medications and ranged in age between 20 and 
65 yrs. old. All studies that used samples collected from human subjects were approved by 
the Institutional Review Board of the University of Utah.
Results
Statistical analysis determined that the limit of detection for the seven automated 
immunoassays were as follows: Access 2 average limit of detection was 0.02 kU/L which was 
within the manufacturers’ claim of 0.50 kU/L; ADVIA Centaur average limit of detection was 0.19
kU/L and the manufacturer’s claim was 0.50 kU/L; ARCHITECT i2000 limit of detection was 0.24
kU/L and the manufacturer’s claim was 0.50 kU/L; AxSYM limit of detection was 0.58 kU/L and 
the manufacturer’s claim was 0.30 kU/L; Elecsys 2010 limit of detection was 0.09 kU/L and the 
manufacturer’s claim of detection was 0.50 kU/L. IMMULITE 2000 limit of detection was 0.15
kU/L and the manufacturer’s claim was 0.50 kU/L; VITROS ECi limit of detection was 0.01 kU/L 
and the manufacturer’s claim was 0.50 kU/L. 
The target value for each linearity sample was calculated based on the samples with the 
lowest and highest concentrations within the analytical measurement range for each method. The 
maximum deviation for a mean recovery from 100% ranged from a low of 6.1% for the Access 2  to 
a high of 12.3% for the Architect i2000. The Access 2 had a maximum  average deviation from the 
mean target recovery of 6.1% (107.4 kU/L)), the ADVIA Centaur had a maximum  average 
deviation from the mean target recovery of 8.8% (52.8 kU/L), the AxSYM had a maximum 
deviation of  6.4% (50.0 kU/L), the ARCHITECT i2000 had a maximum average deviation of 
12.3%, the Elecsys 2010 had a maximum average deviation  from the mean target recovery of 4.7% 
(64.4 kU/L), the IMMULITE 2000 had a maximum average deviation from the mean target recovery 
of 11.6% (14.8 kU/L) and the VITROS ECi had a maximum average deviation from the mean target 
recovery of  9.7% (259.7 kU/L). 
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Figure 1
Conclusions
The limit of detection for six of the seven  automated methods for measuring CA 15-3 
levels were all within acceptable ranges and below  manufacturers’ claims. The one exception 
was the AxSYM  where the manufacturer’s limit of detection was 0.30 kU/L and the 
measured limit of detection was 0.58 kU/L. This should not pose a problem in clinical use.
If 10% is used as the acceptable cutoff, then all the methods evaluated for linearity 
had acceptable maximum deviation from mean recovery  values with the exception of the 
ARCHITECT i2000 and the IMMULITE 2000 where the maximum average deviation from 
target  recovery was 12.3%  and 11.6%, respectively.
All methods demonstrated acceptable imprecision, with  total imprecision levels less 
than 6.1%  for all methods at all three quality control materials tested. 
The  method comparison studies demonstrated varying degrees of agreement with the 
ADVIA Centaur reference method as indicated by the slopes ranging from  0.50 to 1.48, Y 
intercepts ranging from  -5.0 to 7.3 and correlation coefficients ranging from 0.90 to 0.96. 
The ARCHITECT i2000 and the AxSYM  with slopes of 1.07 and 1.06 respectively, showed 
the best agreement. The ARCHITECT i2000 and the AxSYM,  both with  correlation 
coefficients of 0.96 were also the two methods that demonstrated the highest degree of 
correlation with the ADVIA Centaur comparison method. The IMMULITE 2000 and the 
Elecsys 2010 with slopes of 1.10 and 1.15 and correlation coefficients of 0.93  and 0.92 
demonstrated poorer agreement with the reference method. The Access and the VITROS ECi
methods with slopes 0.50 and 1.48 and correlation coefficients of 0.90 and 0.96 respectively, 
demonstrated  considerable bias. 
The upper 97.5% reference limits found were below the manufacturer’s reference 
limits for the Access 2, ADVIA Centaur, ARCHITECT i2000 and the AxSYM. The 
exceptions were the Elecsys 2010, IMMULITE 2000 and VITROS ECi.Overall, all methods 
performed well and are clinically acceptable. However, both method comparison and 
reference interval studies suggest differences between the methods that may be due to 
calibration, assay design, and/or the antibodies used. These methods cannot be used 
interchangeably. 
Figure 1. Comparison of six automated CA 15-3 immunoassay methods. The ADVIA Centaur was used as 
the comparison method. The dashed lines indicate (x=y) and the solid lines indicate the Passing-Bablock
regression. In panel A, the Access 2 method slope was of 0.50, the intercept was 4.4 and r=0.90. In panel B, 
the ARCHITECT i2000 method slope was 1.07, the intercept was –5.0 and r=0.96. In panel C, the AxSYM
method slope was 1.06, the intercept was –1.2 and r=0.96. In panel D, the Elecsys 2010 method slope was 
1.15, the intercept was 1.8 and r=0.92. In panel E, the IMMULITE 2000 method slope was 1.10, the 
intercept was 7.3 and r=0.93. In panel F, the VITROS ECi slope was 1.48, the intercept was 0.3 and r=0.96.  
 
Table 2. Summary of Imprecision Data 
Method Mean CA 15-3 
(kU/L) 
Within Run CV 
(%) 




Access 2     
Level 1 8.4 3.1 0.9 3.2 
Level 2 19.2 3.7 0.0 4.2 
Level 3 none available 
 ADVIA Centaur     
Level 1 14.9 2.7 2.0 3.3 
Level 2 41.8 2.1 1.4 3.1 
Level 3 108.4 3.8 3.4 5.1 
 ARCHITECT    i2000     
Level 1 9.8 2.9 2.8 4.0 
Level 2 30.3 1.9 0.8 2.2 
Level 3 240.0 2.2 2.5 3.3 
 AxSYM     
Level 1 12.2 3.0 0.0 3.0 
Level 2 35.3 0.0 2.4 4.0 
Level 3 144.9 4.0 3.0 5.0 
 Elecsys 2010     
Level 1 13.6 1.9 1.1 2.5 
Level 2 37.4 2.8 0.0 3.4 
Level 3 105.6 3.0 1.7 3.4 
 IMMULITE   2000     
Level 1 16.8 6.1 0.0 6.0 
Level 2 44.2 3.2 1.8 3.8 
Level 3 127.9 4.4 2.9 5.2 
 Vitros ECi     
Level 1 14.1 2.4 0.7 2.6 
Level 2 37.7 2.5 0.0 2.5 
Level 3 186.0 1.6 1.9 2.5 
 
 
Table 3. Summary of Reference Intervals 






Access 2 23.3 31.3 
ADVIA Centaur 30.8 32.4 
ARCHITECT i2000 29.2 31.3 
AxSYM 30.6 31.3 
Elecsys 2010 41.2 31.0 
IMMULITE 2000 42.3 38.0 









Access 2 0.5 - 1000 
ADVIA Centaur 0.5 - 200 
ARCHITECT i2000 0 – 700 
AxSYM 0 – 250 
Elecsys 2010 0 - 300 
IMMULITE 2000 0 – 300 
VITROS ECi 0 - 500 
 
